Épisode 66: Étude FINEARTS-HF
Épisode 66: Finérénone chez les sujets avec insuffisance cardiaque à fraction d’éjection préservée ou légèrement réduite (étude FINEARTS-HF)
Diffusé le 28 octobre 2024
Dans cette 66e baladodiffusion, les Drs Alexandre Mutchmore et Luc Lanthier discutent de d’insuffisance cardiaque à fraction d’éjection préservée ou légèrement réduite et finérénone, en plus de réviser la littérature médicale de septembre 2024.
Quiz clinique (2 min 58), présentation principale (3 min 40), critique (32 min 55), retour sur le cas clinique (44 min 50), autres articles (46 min 57), réponse au quiz clinique (51 min 50)
Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391(16):1475-85. PubMed PMID: 39225278.
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81. PubMed PMID: 13678871.
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67. PubMed PMID: 19001508.
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. PubMed PMID: 24716680.
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42. PubMed PMID: 25406305.
Pfeffer MA, Claggett B. Behind the Scenes of TOPCAT - Bending to Inform. NEJM Evid. 2022 Jan;1(1):EVIDctcs2100007. PubMed PMID: 38319229.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609‑20. PubMed PMID: 31475794.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461PubMed PMID: 34449189.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098. PubMed PMID: 36027570.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-29. PubMed PMID: 33264825.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. PubMed PMID: 34449181.
Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, et al. Time to Significant Benefit of Finerenone in Patients With Heart Failure. J Am Coll Cardiol. 2024. PubMed PMID: 39352338.
Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, et al. Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2024. PubMed PMID: 39332395.
Ekstrom M, Andersson A, Papadopoulos S, Kipper T, Pedersen B, Kricka O, et al. Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia. N Engl J Med. 2024;391(11):977-88. PubMed PMID: 39254466.
Legrand M, Falcone J, Cholley B, Charbonneau H, Delaporte A, Lemoine A, et al. Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. 2024;332(12):970-8. PubMed PMID: 39212270.
Ramacciotti E, Volpiani GG, Britto KF, Agati LB, Ribeiro CM, Aguiar VCR, et al. Rivaroxaban for Patients with Intermittent Claudication. NEJM Evid. 2024;3(9):EVIDoa2400021. PubMed PMID: 39185955.
Crean AM, Adler A, Arbour L, Chan J, Christian S, Cooper RM, et al. Canadian Cardiovascular Society Clinical Practice Update on Contemporary Management of the Patient With Hypertrophic Cardiomyopathy. Can J Cardiol. 2024;40(9):1503-23. PubMed PMID: 38880398.
Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538-700. PubMed PMID: 39210722.
Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-537. PubMed PMID: 39210710.
Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-414. PubMed PMID: 39210723.
Kohler TS, Kloner RA, Rosen RC, Burnett AL, Blaha MJ, Ganz P, et al. The Princeton IV Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clin Proc. 2024;99(9):1500-17. PubMed PMID: 39115509.
Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024;119(9):1730-53.
Moody WE, Turvey-Haigh L, Knight D, Coats CJ, Cooper RM, Schofield R, et al. British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis. Echo Res Pract. 2023;10(1):13. PubMed PMID: 37653443.
Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, et al. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. Can J Cardiol. 2020;36(3):322-334. PubMed PMID: 32145862.
